| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0006-3223(00)01111-2 |
| P698 | PubMed publication ID | 11230876 |
| P2093 | author name string | Zhang Y | |
| Yang J | |||
| Zeng H | |||
| Menon NK | |||
| Peng L | |||
| Shao H | |||
| Zagorski MG | |||
| Salomon AR | |||
| Freidland RP | |||
| P2860 | cites work | beta-Amyloid(1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology | Q22253223 |
| Solution structure of residues 1-28 of the amyloid beta-peptide | Q27729371 | ||
| Solution structure of amyloid beta-peptide(1-40) in a water-micelle environment. Is the membrane-spanning domain where we think it is? | Q27764923 | ||
| Aging renders the brain vulnerable to amyloid beta-protein neurotoxicity | Q28276393 | ||
| Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins | Q29547593 | ||
| Discovering high-affinity ligands for proteins: SAR by NMR | Q29617569 | ||
| Pulsed field gradient multi-dimensional NMR methods for the study of protein structure and dynamics in solution | Q30423645 | ||
| High-throughput nuclear magnetic resonance-based screening | Q30729199 | ||
| Solution structures of micelle-bound amyloid beta-(1-40) and beta-(1-42) peptides of Alzheimer's disease | Q31939978 | ||
| Translating cell biology into therapeutic advances in Alzheimer's disease | Q33678168 | ||
| Prospects for pharmacological intervention in Alzheimer disease | Q33893713 | ||
| Structural analysis of Alzheimer's beta(1-40) amyloid: protofilament assembly of tubular fibrils. | Q34167200 | ||
| Transthyretin sequesters amyloid beta protein and prevents amyloid formation | Q35700645 | ||
| 1H NMR of A beta amyloid peptide congeners in water solution. Conformational changes correlate with plaque competence | Q36699602 | ||
| Nuclear and cytoplasmic localization of the beta-amyloid peptide (1-43) in transfected 293 cells | Q36796585 | ||
| Intracellular accumulation and resistance to degradation of the Alzheimer amyloid A4/beta protein | Q37149874 | ||
| The toxicity in vitro of beta-amyloid protein | Q40422520 | ||
| Epidemiology and neurobiology of the multiple determinants of Alzheimer's disease | Q40580720 | ||
| Pharmacology of nicotine: addiction and therapeutics | Q41048262 | ||
| Amyloid, the presenilins and Alzheimer's disease | Q41433661 | ||
| Mechanisms of neurotoxicity associated with amyloid beta deposition and the role of free radicals in the pathogenesis of Alzheimer's disease: a critical appraisal | Q41485841 | ||
| In vitro aging of beta-amyloid protein causes peptide aggregation and neurotoxicity | Q44418518 | ||
| Soluble amyloid Abeta-(1-40) exists as a stable dimer at low concentrations | Q46204569 | ||
| The levels of soluble versus insoluble brain Abeta distinguish Alzheimer's disease from normal and pathologic aging | Q48156883 | ||
| High levels of circulating Abeta42 are sequestered by plasma proteins in Alzheimer's disease | Q48233908 | ||
| Nicotinic receptor stimulation protects neurons against beta-amyloid toxicity. | Q48649195 | ||
| Aggregation and secondary structure of synthetic amyloid beta A4 peptides of Alzheimer's disease | Q48770682 | ||
| Morphology and toxicity of Abeta-(1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's disease | Q48940326 | ||
| In vitro growth of Alzheimer's disease beta-amyloid plaques displays first-order kinetics | Q49161050 | ||
| Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. | Q51983988 | ||
| Solution Structures of β Peptide and Its Constituent Fragments: Relation to Amyloid Deposition | Q53182604 | ||
| Evidence that Aβ42 is the real culprit in alzheimer's disease | Q53201642 | ||
| Soluble multimeric Alzheimer beta(1-40) pre-amyloid complexes in dilute solution. | Q53210234 | ||
| Nicotine inhibits amyloid formation by the beta-peptide. | Q53214439 | ||
| Smoking and oestrogen-replacement therapy as protective factors for Alzheimer's disease. | Q53216125 | ||
| The origins of Alzheimer disease: a is for amyloid. | Q53233941 | ||
| Methodological advances in protein NMR | Q60680251 | ||
| Amyloid beta-peptide is transported on lipoproteins and albumin in human plasma | Q71860042 | ||
| Nicotine modulates the neurotoxic effect of beta-amyloid protein(25-35)) in hippocampal cultures | Q73176021 | ||
| Fibrillogenesis of Alzheimer Abeta peptides studied by fluorescence energy transfer | Q73433573 | ||
| Structural studies of soluble oligomers of the Alzheimer beta-amyloid peptide | Q73514544 | ||
| Interaction of Alzheimer beta-amyloid peptide(1-40) with lipid membranes | Q73940275 | ||
| Cerebrospinal fluid A beta42 is increased early in sporadic Alzheimer's disease and declines with disease progression | Q77351145 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | nicotine | Q12144 |
| P304 | page(s) | 248-257 | |
| P577 | publication date | 2001-02-01 | |
| P1433 | published in | Biological Psychiatry | Q4914961 |
| P1476 | title | Nicotine and amyloid formation | |
| P478 | volume | 49 |
| Q28740910 | A cyclic undecamer peptide mimics a turn in folded Alzheimer amyloid β and elicits antibodies against oligomeric and fibrillar amyloid and plaques |
| Q47095504 | Alzheimer's disease and cigarette smoke components: effects of nicotine, PAHs, and Cd(II), Cr(III), Pb(II), Pb(IV) ions on amyloid-β peptide aggregation |
| Q48685462 | Alzheimer's disease: halothane induces Abeta peptide to oligomeric form--solution NMR studies |
| Q36825498 | Antibodies to potato virus Y bind the amyloid beta peptide: immunohistochemical and NMR studies |
| Q46980744 | Antioxidant compounds have potent anti-fibrillogenic and fibril-destabilizing effects for alpha-synuclein fibrils in vitro |
| Q46692906 | Attenuation of Abeta deposition in the entorhinal cortex of normal elderly individuals associated with tobacco smoking. |
| Q21131066 | Beneficial effects of nicotine, cotinine and its metabolites as potential agents for Parkinson's disease |
| Q34121565 | Beyond the cholinergic hypothesis: do current drugs work in Alzheimer's disease? |
| Q35687034 | Chronic stress and Alzheimer's disease-like pathogenesis in a rat model: prevention by nicotine |
| Q37855869 | Computational insights into the development of novel therapeutic strategies for Alzheimer's disease |
| Q30434143 | Drugs of abuse that mediate advanced glycation end product formation: a chemical link to disease pathology |
| Q57822469 | Effect of smoking cessation on the risk of dementia: a longitudinal study |
| Q44605317 | Glutamate and Amyloid β-Protein Rapidly Inhibit Fast Axonal Transport in Cultured Rat Hippocampal Neurons by Different Mechanisms |
| Q34207086 | Glycation of the amyloid beta-protein by a nicotine metabolite: a fortuitous chemical dynamic between smoking and Alzheimer's disease |
| Q35046164 | Nicotine attenuates beta-amyloid peptide-induced neurotoxicity, free radical and calcium accumulation in hippocampal neuronal cultures |
| Q44193624 | Nicotine breaks down preformed Alzheimer's beta-amyloid fibrils in vitro |
| Q30278808 | Nicotine mediates expression of genes related to antioxidant capacity and oxidative stress response in HIV-1 transgenic rat brain |
| Q43233908 | Nicotine reduces the cytotoxic effect of glycated proteins on microglial cells |
| Q38558352 | Perspectives on Inhibiting β-Amyloid Aggregation through Structure-Based Drug Design |
| Q34055011 | Role of vascular risk factors and vascular dysfunction in Alzheimer's disease |
| Q36911406 | Small molecule inhibitors of Abeta assembly |
| Q39832389 | Structurally distinct toxicity inhibitors bind at common loci on β-amyloid fibril |
| Q39622197 | Surface plasmon resonance based biosensors for exploring the influence of alkaloids on aggregation of amyloid-β peptide |
| Q87354667 | Targeted studies on the interaction of nicotine and morin molecules with amyloid β-protein |
| Q46230541 | The polyphenol piceid destabilizes preformed amyloid fibrils and oligomers in vitro: hypothesis on possible molecular mechanisms |
| Q34212626 | α7 Nicotinic receptor activation reduces β-amyloid-induced apoptosis by inhibiting caspase-independent death through phosphatidylinositol 3-kinase signaling |
Search more.